Senior Management Team

Mark A. Sirgo, Pharm. D.

President and Chief Executive Officer

Mark A. Sirgo, Pharm.D. has been our President and Chief Executive Officer since July 2005. Dr. Sirgo joined our company in August 2004 as Senior Vice President of Commercialization and Corporate Development upon the acquisition of Arius Pharmaceuticals, of which Dr. Sirgo was a co-founder and Chief Executive Officer. Dr. Sirgo has also served as our Executive Vice President, Corporate and Commercial Development, and Chief Operating Officer. Dr. Sirgo has more than 20 years of experience in the pharmaceutical industry, including 16 years in clinical drug development; seven years in marketing, sales, and business development, and five years in executive management. Prior to his involvement with Arius Pharmaceuticals from 2003 to 2004, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc. Dr. Sirgo serves on the Board of Salix Pharmaceuticals (Nasdaq: SLXP), a specialty pharmaceutical company specializing in gastrointestinal products. Dr. Sirgo received his Bachelor of Science in Pharmacy from Ohio State University and his Doctorate from the Philadelphia College of Pharmacy and Science.

Andrew L. Finn, Pharm.D.

Executive Vice President of Product Development

Andrew Finn, Pharm.D. has been our Executive Vice President of Product Development since January 2007. He joined the company in August 2004, upon our acquisition of Arius Pharmaceuticals, of which he was co-founder and Executive Vice President Clinical Development and Regulatory Affairs. Dr. Finn has nearly 30 years of experience in pharmaceutical product development and has played a major role in the development and regulatory approval of 6 individual products over his career, He is responsible for the development of BioDelivery Sciences' portfolio of products (e.g. BEMA® Buprenorphine for chronic pain, BEMA Buprenorphine with Naloxone for opioid dependence, and BEMA Granistron for nausea and vomiting) including pharmaceutical development and manufacturing, nonclinical and clinical development, regulatory affairs and quality assurance. Prior to his involvement with Arius, Dr. Finn was the Executive Vice President of Product Development at POZEN, Inc., where he had similar responsibilities to those at BDSI, he was the co-founder and Chief Executive Officer of enVision Sciences, a regulatory and clinical service company, Vice President of U.S. Clinical Research for Solvay Pharmaceuticals, and held a number of positions with increasing responsibility during his 10 year tenure at Glaxo, Inc. Dr. Finn received his Bachelor of Science in Pharmacy from the University of North Carolina and his Doctorate from the University of Michigan

James A. McNulty, CPA

Chief Financial Officer

James A. McNulty, CPA, has served as our Secretary, Treasurer and Chief Financial Officer since 2001. He also serves as Chief Financial Officer of Hopkins Capital Group, an affiliation of limited liability companies which engage in venture activities and is Treasurer and Corporate Secretary of Accentia Biopharmaceuticals, Inc. (Nasdaq: ABPI). Mr. McNulty practiced public accounting from 1971 through 1997 and co-founded Pender McNulty & Newkirk, which became one of Florida's largest regional CPA firms and was a founder/principal in two other CPA firms. He served as Chief Financial Officer of Star Scientific, Inc. (Nasdaq: STSI) from October 1998 to May 2000. From June 2000 through January 2002, he served as Chief Financial Officer and Chief Operating Officer of American Prescription Providers, Inc. Mr. McNulty is a graduate of University of South Florida, a licensed Certified Public Accountant and a member of the American and Florida Institutes of CPAs, and the Financial Executives International.

Benny Ward, CPA

Benny Ward

Executive Vice-President of Business and Strategic Development

Benny Ward, CPA, has been our Executive Vice-President of Business and Strategic Development since September 2010. Mr. Ward has more than 15 years of financial, operations and management experience, including 12 with life science companies. He most recently served as VP of Finance and CFO of venture backed InnerPulse, Inc., a development stage cardiac rhythm management device company. Prior to joining InnerPulse, Mr. Ward was VP of Finance and CFO of Closure Medical Corporation, a world-leading, publicly traded developer and manufacturer of biomaterial-based medical adhesives that was acquired by Johnson & Johnson in June 2005. He joined Closure Medical in 1996 serving as a key member of the management team from the Company's successful initial public offering through its 2005 sale to Johnson & Johnson. Before joining Closure Medical, he spent three years as an auditor for Price Waterhouse. Benny serves on the Advisory Board of the School of Business at East Carolina University and is a board member of the Children's Flight of Hope. Mr. Ward received his Bachelor of Science degree in Accounting and Bachelor of Arts degree in Political Science from East Carolina University.

Steven Dykstra

Senior Vice President of Manufacturing Operations

Steven Dykstra was appointed our Senior Vice President of Manufacturing Operations in January 2011. He joined the company with over 30 years experience in the development and manufacture of pharmaceutical products. Steve is responsible for the execution of all manufacturing operations conducted by the organization to maintain adequate product supply for ONSOLIS^® and to bring our product candidates successfully to market. Steve started his career with Baxter Travenol and assumed positions of increasing responsibility working for American Critical Care, Dupont Pharmaceuticals, DuPont Merck Pharmaceuticals, MGI Pharma, and finally IVX Animal Health/Teva where he was Vice President of Manufacturing Operations. He has also worked as a consultant in Manufacturing Operations. He has 14 years experience with outsourced development, manufacturing, and distribution while at MGI Pharma where he was Senior Director of Manufacturing Operations. Steve received a BS in Chemistry from Illinois State University. Steve was certified in the American Production and Inventory Control Society in Production and Inventory Management (APICS-CPIM) in 1998. He is the inventor of two patents related to healthcare and he has been published in the American Journal of Hospital Pharmacy.

Albert J. Medwar, M.B.A.

Vice President, Marketing and Corporate Development

Albert J. Medwar, M.B.A. has been our Vice President of Marketing since joining the company in April 2007, with nearly 20 years of experience in marketing, sales, and marketing research. Prior to joining the company, Mr. Medwar was the Head of Oncology Marketing at EMD Pharmaceuticals, the U.S. subsidiary of Merck KGaA, where he was responsible for developing the global market for a pipeline of oncology products. Mr. Medwar was also the Marketing Director for Triangle Pharmaceuticals, a start-up company focusing on the development and commercialization of compounds for HIV and hepatitis. Mr. Medwar's pharmaceutical career began in sales at Burroughs Wellcome, which later became Glaxo Wellcome. After six years of sales experience, he took on marketing research responsibilities, and then played an important role in the launch of a short acting opioid analgesic, remifentanil, and held increasing marketing responsibility for a number of products including a portfolio of anesthetic/analgesic agents, Zofran, and Wellbutrin SR. Mr. Medwar received a Bachelor of Science degree from Cornell University and a Masters of Business Administration from Bentley College.

Niraj Vasisht, Ph.D.

Senior Vice President, Product Development & Chief Technical Officer

Niraj Vasisht, Ph.D. has been our Senior Vice President of Product Development and Chief Technology Officer since October 2008. He joined the company in February 2005 as the Vice President of Product Development. He has over 16 years of experience in pharmaceutical development. Dr. Vasisht's heads the pharmaceutical development and clinical trial manufacturing operations for our product candidates. He is responsible for the product design and development of BDSI pipeline products. His expertise is in drug delivery technology, and he provides technical and strategic leadership to the business development function. In his position, he evaluates suitability of drug candidates into the delivery platform, creates intellectual property for product composition and manufacturing processes, provides direction to pipeline extension strategies, and oversees contract CTM manufacturing operations. He oversees the product design, formulation development, quality control, process engineering, validation and stability testing of the drug product. From 1994 to 2005, Dr. Vasisht held positions of increasing responsibility at Southwest Research Institute where he ultimately served as the Director of Microencapsulation, Pharmaceutical Development and Nanomaterials and was responsible for leading the group that provides research and development and product development services to pharmaceutical, consumer health, and nutraceutical companies. Dr. Vasisht is the inventor/co-inventor on multiple patents in drug delivery, and has over 35 publications. Dr. Vasisht received a Bachelor's degree in Chemical Engineering from the Indian Institute of Technology at Kanpur, a Master's from the University of New Hampshire and a Doctorate in Chemical Engineering from Rensselaer Polytechnic Institute.